Characteristics, therapeutic pathway and the economic burden of patients with drug‐resistant epilepsy: A real‐world analysis following the introduction of cenobamate in Italy
This real-world study highlights a progressively earlier adoption of cenobamate in Italy over the last few years, with patients starting after fewer prior treatments. Compared to patients potentially eligible but untreated with cenobamate, those receiving cenobamate showed greater treatment persistence, reduced polypharmacy, fewer hospitalizations, and fewer neurological visits. Despite higher drug costs, overall health care efficiency improved, supporting its potential as an effective earlier-line option.
Authors
- Valentina Perrone (ORCID: https://orcid.org/0000-0001-5018-490X)
- Maria Cappuccilli (ORCID: https://orcid.org/0000-0002-2592-9532)
- Stefania Dell'orco
- Antonella Lavalle
- P Schiavone
- Alessandro Brega
- Chiara Veronesi (ORCID: https://orcid.org/0000-0003-2852-2022)
- Daniela Mancini (ORCID: https://orcid.org/0000-0001-6653-9322)
- Domenico Lucatelli
- Loredana Ubertazzo
- Cataldo Procacci (ORCID: https://orcid.org/0000-0001-9505-4340)
- Adriano Vercellone
- Chiara Scandolara
- Margherita Andretta (ORCID: https://orcid.org/0000-0002-4072-2783)
- Luca Degli Esposti (ORCID: https://orcid.org/0000-0002-7020-6659)
- Romina Pagliaro
- Fausto Bartolini
- Marcello Bacca
- Maria Rosaria Cillo
- Stefano Grego
- Paola Valpondi
- Alberto Zucchi (ORCID: https://orcid.org/0000-0002-1522-4029)
- Antonietta Barbieri
- Andrea Luciani
- Fulvio Ferrante
- Maurizio Pastorello
- Maria Ciappetta
- Francesco Colasuonno
Institutions
- University of Bergamo (IT)
- University of Salerno (IT)
- Centro Studi GISED (IT)
- Rina Services (Italy) (IT)
- Farm Foundation (US)
- Fidia Farmaceutici (Italy) (IT)
- ASL Roma (IT)
- 2D Formazione (Italy) (IT)
- AULSS 2 Marca Trevigiana (IT)
- Ospedale A. Perrino (IT)
- Azienda Sanitaria Locale di Asti (IT)
- Molteni Farmaceutici (Italy) (IT)
- Ospedale San Bassiano (IT)
- Azienda Socio Sanitaria Territoriale Lariana (IT)
- Istituto di Farmacologia Traslazionale (IT)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Farmaceutici Damor (Italy) (IT)
- Azienda Sanitaria Locale Roma 3 (IT)
- Angelini Pharma (Italy) (IT)
- University of Palermo (IT)
Publication Details
- Journal
- Epilepsia
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1111/epi.18673
- Citations
- 2
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Angelini Pharma